DXCM250110P65000
- 0.29
- 0.000.00%
DexCom Newsroom
Billionaire Chase Coleman III Completely Sells Out of DexCom and Gambles the Proceeds on This Stock
Unusual Options Activity: AMZN, PCG and Others Attract Market Bets, AMZN V/OI Ratio Reaches 277.0
EST Jan 10th Closing Delivery - In the last three hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
Bernstein Maintains DexCom(DXCM.US) With Buy Rating, Raises Target Price to $89
Why Is Jim Cramer Mystified by DexCom, Inc. (DXCM)'s Earnings Miss and Competitive Challenges?
Bernstein Maintains DexCom(DXCM.US) With Buy Rating, Cuts Target Price to $86
RBC Capital Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $115
RBC Capital Reaffirms Their Buy Rating on Dexcom (DXCM)
Dexcom to Present at 43rd Annual J.P. Morgan Healthcare Conference
Wells Fargo Spotlights 31 Names It Believes 'Offer Above-average Growth Potential'
Wearable Patch Market Report 2025, With Profiles of Key Players Abbott, Medtronic, Dexcom, GlucoWatch, IRhythm Technologies, Insulet, Tactile Medical, VitalConnect, Qardio Myant & BioTelemetry
DexCom's (NASDAQ:DXCM) Returns On Capital Are Heading Higher
Chevron, PayPal Stock and These 8 US Names Are Best Ideas for Q1 2025 at BofA
The U.S. stock market officially closed for 2024! Among the components of the three major stock indices, who performed the best and who performed the worst?
AppLovin, a constituent stock of the Nasdaq, surged by 713%, becoming the biggest dark horse, with an increase more than four times that of AI leader NVIDIA.
These Are the Best and Worst Stocks This Year
DexCom Insiders Sold US$18m Of Shares Suggesting Hesitancy
Earnings Tell The Story For DexCom, Inc. (NASDAQ:DXCM)
At US$80.57, Is DexCom, Inc. (NASDAQ:DXCM) Worth Looking At Closely?
Abbott, DexCom Settlement 'Not a Complete Surprise,' Says Wells Fargo
Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $94
Express News | Abbott Laboratories announced that it has reached an agreement with Medical Devices company DexCom to resolve all patent disputes between the two parties regarding continuous glucose monitoring devices.